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A 29-year-old man presenting with a retroperitoneal mass was found to have a testis lesion consistent
with mixed germ cell tumor and the RPLND specimen showed teratoma with an area of central nervous
system-type primitive neuroectodermal tumor (PNET) not present in the testis. Whether such primitive
tumor components represent a de novo tumor component or represent progression from existing
neuroepithelial teratomatous elements is unclear. Given the high likelihood of residual tumor and
possibility of malignant transformation, post-chemotherapy RPLND remains vital in treating patients
with testis cancer. PNET is chemo-resistant and lesions should be resected, without clear evidence for
adjuvant chemotherapy.
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Case presentation
A previously healthy 29-year-old man presented with inter-
mittent right lower quadrant and ﬂank pain. On computed to-
mography (CT) he was found to have a right-sided retroperitoneal
mass measuring 13  11  7 cm, encasing the aorta, compressing
the inferior vena cava and right ureter, and causing moderate
hydronephrosis (Fig.1). Testis tumormarkers were signiﬁcant for a-
fetoprotein (AFP) of 1960 ug/l, lactate dehydrogenase (LDH) of
863 U/l, and b-human chorionic gonadotropin (HCG) of less than
0.5 IU/l. Scrotal ultrasound revealed two small discrete adjacent
right intratesticular lesions, 12 9 11mm and 9 6 6mmwith
a normal contralateral testis. Pathologic examination of the orchi-
ectomy revealed a 2 cm mixed germ cell tumor (50% seminoma,
classic type and 50% teratoma without immature elements) that
was partially necrotic and surrounded by organizing granulation
tissue and scar. The tumor did not extend beyond the testicular
parenchyma and did not involve lymphovascular spaces or the cord
margin. Post-operative markers remained elevated (AFP 2433, LDH
656, hCG <0.5). As IGCCCG intermediate-risk (T1N3M0S2) he un-
derwent 3 cycles of bleomycin, etoposide, and cisplatin and afteran Francisco, Department of
n Francisco, CA 94143, USA.
eng).
Inc. This is an open access article udeveloping a dry cough, his fourth cycle was limited to etoposide
and cisplatin. His tumor markers normalized and he underwent a
retroperitoneal lymph node dissection (RPLND). Pathology revealed
an 8 cm metastasis composed of teratoma and seminoma plus aFigure 1. Primitive neuroectodermal tumor cells formed a 2 cm mass within the 8 cm
retroperitoneal metastasis composed of seminoma and teratoma (not shown); inset
shows diffuse immunohistochemical expression of synaptophysin whereas all germ
cell immunostains were negative (not shown).
nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 2. Computed Tomography demonstrating large right-sided retroperitoneal
mass, measuring 13  11  7 cm, encasing the aorta and compressing the inferior vena
cava and right ureter.
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cells resembling malignant primitive neural elements. The primi-
tive tumor cells showed immunohistochemical expression of syn-
aptophysin but not of CD99 (Fig. 2). Embryonal carcinoma and
rhabdomyosarcoma were excluded by immunohistochemistry
(negative SALL4, OCT4, desmin and myogenin). The morphology
and immunophenotype of the cells in question was classiﬁed as a
form of central nervous system-type primitive neuroectodermal
tumor (CNS-type PNET). Re-examination of the slides of the pri-
mary testicular tumor did not reveal any similar tumor component
but it was not possible to determine the tumor type that originally
occupied the areas of necrosis and scar adjacent to viable seminoma
and teratoma.
Discussion
Teratomas represent approximately 4% of testicular germ cell
tumors, but display complex histology and a heterogeneous clinical
progression.1 Although some may be inert or only locally aggres-
sive, 3e8% of testicular teratomas have the potential for trans-
formation of the epithelial elements to carcinoma or mesenchymal
elements to sarcoma. Rarely, primary or metastatic testicular germ
cell tumors may contain tumor components that morphologically
resemble central nervous system medulloblastoma or medulloe-
pithelioma (so-called CNS-type PNET) or Ewing sarcoma(previously referred to as peripheral-type PNET).2 Although the
CNS-type PNETs may morphologically resemble Ewing sarcoma,
the latter harbor a pathognomonic translocation of the EWSR1 gene
on chromosome 22 and are CD99 positive, whereas the former are
not. A recent study demonstrated that EWSR1 translocations are not
present in testicular tumors that contain PNET-like tumors.3
Therefore these tumor components are not Ewing sarcoma but a
form of CNS-type PNET.Whether such primitive tumor components
represent a de novo tumor component or represent progression
from existing neuroepithelial teratomatous elements is unclear. The
current case is best classiﬁed as CNS-type PNET as the CD99 stain
was negative and synaptophysin was positive.
Post-chemotherapy RPLND remains an important component of
treatment for patients with residual masses. Approximately half of
patients have only residual scar, 40% have teratoma, and 10% have
viable tumor. Recent work showed that even in patients with
residual masses 20 mm after contemporary chemotherapy regi-
mens, 7% and 26% had viable tumor and teratoma, respectively.4
Conclusion
Given the high likelihood of residual tumor and possibility of
malignant transformation of teratoma into aggressive histology,
post-chemotherapy RPLND remains vital in treating patients with
testis cancer. In addition, PNET is chemo-resistant and recurrent
lesions should be resected, without clear evidence for adjuvant
chemotherapy in this setting.
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